Download PDF
Endoscopy 2021; 53(01): 6-14
DOI: 10.1055/a-1195-1000
Systematic review

Spatial distribution of dysplasia in Barrett’s esophagus segments before and after endoscopic ablation therapy: a meta-analysis

Shashank Garg‡   *
1   Division of Gastroenterology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
,
Jesse Xie‡   *
2   Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
,
Sumant Inamdar
1   Division of Gastroenterology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
,
Sheila L. Thomas
3   Education and Research Services, UAMS Library, Little Rock, Arkansas, USA
,
Arvind J. Trindade
4   Division of Gastroenterology, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New Hyde Park, New York, USA
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints


Referred to by:

Author commentary on Shashank Garg et al.Endoscopy 2021; 53(01): v6-v6
DOI: 10.1055/a-1211-1663

Abstract

Background Dysplasia in Barrett’s esophagus (BE) is focal and difficult to locate. The aim of this meta-analysis was to understand the spatial distribution of dysplasia in BE before and after endoscopic ablation therapy.

Methods A systematic search was performed of multiple databases to July 2019. The location of dysplasia prior to ablation was determined using a clock-face orientation (right or left half of the esophagus). The location of the dysplasia post-ablation was classified as within the tubular esophagus or at the top of the gastric folds (TGF).

Results 13 studies with 2234 patients were analyzed. Pooled analysis from six studies (819 lesions in 802 patients) showed that before ablation, dysplasia was more commonly located in the right half versus the left half (odds ratio [OR] 4.3; 95 % confidence interval [CI] 2.33 – 7.93; P < 0.001). Pooled analysis from seven studies showed that dysplasia after ablation recurred in 101 /1432 patients (7.05 %; 95 %CI 5.7 % – 8.4 %). Recurrence of dysplasia was located more commonly at the TGF (n = 68) than in the tubular esophagus (n = 34; OR 5.33; 95 %CI 1.75 – 16.21; P = 0.003). Of the esophageal lesions, 90 % (27 /30) were visible, whereas only 46 % (23 /50) of the recurrent dysplastic lesions at the TGF were visible (P < 0.001).

Conclusion Before ablation, dysplasia in BE is found more frequently in the right half of the esophagus versus the left. Post-ablation recurrence is more commonly found in the TGF and is non-visible, compared with the tubular esophagus, which is mainly visible.

* Contributed equally to this manuscript


Supplementary material



Publication History

Received: 11 February 2020
Received: 05 June 2020

Accepted: 05 June 2020

Accepted Manuscript online:
05 June 2020

Article published online:
08 July 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Spechler SJ, Souza RF. Barrett’s Esophagus. NEJM 2014; 371: 836-845
    CrossrefPubMedGoogle Scholar
  • 2 Trindade AJ, Navaneethan U, Aslanian HR. et al. Advances in the diagnosis and surveillance of Barrett’s esophagus (with videos). Gastrointest Endosc 2019; 90: 325-334
    CrossrefPubMedGoogle Scholar
  • 3 Anandasabapathy S. Advanced imaging in Barrett’s esophagus: are we ready to relinquish the random?. Clin Gastroenterol Hepatol 2013; 11: 1571-1572
    CrossrefPubMedGoogle Scholar
  • 4 Antony A, Pohanka C, Keogh S. et al. Adherence to quality indicators in endoscopic surveillance of Barrett’s esophagus and correlation to dysplasia detection rates. Clin Res Hepatol Gastroenterol 2018; 42: 591-596
    CrossrefPubMedGoogle Scholar
  • 5 Sharma P, Katzka DA, Gupta N. et al. Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology 2015; 149: 1599-1606
    CrossrefPubMedGoogle Scholar
  • 6 Cerrone SA, Trindade AJ. Advanced imaging in surveillance of Barrett’s esophagus: Is the juice worth the squeeze?. World J Gastroenterol 2019; 25: 3108-3115
    CrossrefPubMedGoogle Scholar
  • 7 Qumseya BJ, Wang H, Badie N. et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett’s esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 2013; 11: 1562-70.e1-e2
    CrossrefPubMedGoogle Scholar
  • 8 Waterhouse DJ, Fitzpatrick CRM, di Pietro M. et al. Emerging optical methods for endoscopic surveillance of Barrett’s oesophagus. Lancet Gastroenterol Hepatol 2018; 3: 349-362
    CrossrefPubMedGoogle Scholar
  • 9 Alshelleh M, Inamdar S, McKinley M. et al. Incremental yield of dysplasia detection in Barrett’s esophagus using volumetric laser endomicroscopy with and without laser marking compared with a standardized random biopsy protocol. Gastrointest Endosc 2018; 88: 35-42
    CrossrefPubMedGoogle Scholar
  • 10 Sharma P, Falk GW, Weston AP. et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572
    CrossrefPubMedGoogle Scholar
  • 11 Bibbò S, Ianiro G, Ricci R. et al. Barrett’s oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. Dig Liver Dis 2016; 48: 1043-1047
    CrossrefPubMedGoogle Scholar
  • 12 Enestvedt BK, Lugo R, Guarner-Argente C. et al. Location, location, location: does early cancer in Barrett’s esophagus have a preference?. Gastrointest Endosc 2013; 78: 462-467
    CrossrefPubMedGoogle Scholar
  • 13 Pech O, Gossner L, Manner H. et al. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy 2007; 39: 588-593
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Kariyawasam VC, Bourke MJ, Hourigan LF. et al. Circumferential location predicts the risk of high-grade dysplasia and early adenocarcinoma in short-segment Barrett’s esophagus. Gastrointest Endosc 2012; 75: 938-944
    CrossrefPubMedGoogle Scholar
  • 15 Cotton CC, Duits LC, Wolf WA. et al. Spatial predisposition of dysplasia in Barrett’s esophagus segments: a pooled analysis of the SURF and AIM dysplasia trials. Am J Gastroenterol 2015; 110: 1412-1419
    CrossrefPubMedGoogle Scholar
  • 16 Omar M, Thaker AM, Wani S. et al. Anatomic location of Barrett’s esophagus recurrence after endoscopic eradication therapy: development of a simplified surveillance biopsy strategy. Gastrointest Endosc 2019; 90: 395-403
    CrossrefPubMedGoogle Scholar
  • 17 Eluri S, Earasi AG, Moist SE. et al. Prevalence and incidence of intestinal metaplasia and dysplasia of gastric cardia in patients with Barrett’s esophagus after endoscopic therapy. Clin Gastroenterol Hepatol 2020; 18: 82-88.e1
    CrossrefPubMedGoogle Scholar
  • 18 Sami SS, Ravindran A, Kahn A. et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study. Gut 2019; 68: 1379-1385
    CrossrefPubMedGoogle Scholar
  • 19 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700-b2700
    CrossrefPubMedGoogle Scholar
  • 20 Bahin FF, Jayanna M, Hourigan LF. et al. Long-term outcomes of a primary complete endoscopic resection strategy for short-segment Barrett’s esophagus with high-grade dysplasia and/or early esophageal adenocarcinoma. Gastrointest Endosc 2016; 83: 68-77
    CrossrefPubMedGoogle Scholar
  • 21 Pech O, Gossner L, Manner H. et al. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy 2007; 39: 588-593
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Cassani L, Sumner E, Slaughter JC. et al. Directional distribution of neoplasia in Barrett’s esophagus is not influenced by distance from the gastroesophageal junction. Gastrointest Endosc 2013; 77: 877-882
    CrossrefPubMedGoogle Scholar
  • 23 Conio M, Fisher DA, Blanchi S. et al. One-step circumferential endoscopic mucosal cap resection of Barrett’s esophagus with early neoplasia. Clin Res Hepatol Gastroenterol 2014; 38: 81-91
    CrossrefPubMedGoogle Scholar
  • 24 Jego M, Volant A, Faycal J. et al. Prevalence and topography of intestinal metaplasia in columnar lined esophagus. Gastroenterol Clin Biol 2007; 31: 601-606
    CrossrefPubMedGoogle Scholar
  • 25 Konda VJA, Gonzalez HabaRuiz M, Koons A. et al. Complete endoscopic mucosal resection is effective and durable treatment for Barrett’s-associated neoplasia. Clin Gastroenterol Hepatol 2014; 12: 2002-2010.e1-e2
    CrossrefPubMedGoogle Scholar
  • 26 Mino-Kenudson M, Ban S, Ohana M. et al. Buried dysplasia and early adenocarcinoma arising in Barrett esophagus after porfimer-photodynamic therapy. Am J Surg Pathol 2007; 31: 403-409
    CrossrefPubMedGoogle Scholar
  • 27 Pouw RE, Gondrie JJ, Sondermeijer CM. et al. Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg 2008; 12: 1627-1636 ; discussion 1636-1637
    CrossrefPubMedGoogle Scholar
  • 28 Yasuda K, Choi SE, Nishioka NS. et al. Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett’s esophagus. Dig Dis Sci 2014; 59: 1560-1566
    CrossrefPubMedGoogle Scholar
  • 29 Cameron G, Desmond P, Jayasekera C. et al. Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign. Endosc Int Open 2016; 04: E849-E858
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Cotton CC, Wolf WA, Pasricha S. et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: endoscopic findings and anatomic location. Gastrointest Endosc 2015; 81: 1362-1369
    CrossrefPubMedGoogle Scholar
  • 31 Halsey KD, Chang JW, Waldt A. et al. Recurrent disease following endoscopic ablation of Barretts high-grade dysplasia with spray cryotherapy. Endoscopy 2011; 43: 844-848
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Ramay FH, Cui Q, Greenwald BD. Outcomes after liquid nitrogen spray cryotherapy in Barrett’s esophagus–associated high-grade dysplasia and intramucosal adenocarcinoma: 5-year follow-up. Gastrointest Endosc 2017; 86: 626-632
    CrossrefPubMedGoogle Scholar
  • 33 Sami SS, Ravindran A, Kahn A. et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study. Gut 2019; 68: 1379-1385
    CrossrefPubMedGoogle Scholar
  • 34 Vaccaro BJ, Gonzalez S, Poneros JM. et al. Detection of intestinal metaplasia after successful eradication of Barrett’s Esophagus with radiofrequency ablation. Dig Dis Sci 2011; 56: 1996-2000
    CrossrefPubMedGoogle Scholar
  • 35 Skrobić O, Simić A, Radovanović N. et al. Significance of Nissen fundoplication after endoscopic radiofrequency ablation of Barrett’s esophagus. Surg Endosc 2016; 30: 3802-3807
    CrossrefPubMedGoogle Scholar
  • 36 van Vilsteren FGI, Pouw RE, Seewald S. et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011; 60: 765-773
    CrossrefPubMedGoogle Scholar
  • 37 Herrero LA, van Vilsteren FGI, Pouw RE. et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett’s esophagus longer than 10 cm. Gastrointest Endosc 2011; 73: 682-690
    CrossrefPubMedGoogle Scholar
  • 38 Tan MC, Kanthasamy KA, Yeh AG. et al. Factors associated with recurrence of Barrett’s esophagus after radiofrequency ablation. Clin Gastroenterol Hepatol 2019; 17: 65-72.e5
    CrossrefPubMedGoogle Scholar
  • 39 Phoa KN, Pouw RE, van Vilsteren FGI. et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145: 96-104
    CrossrefPubMedGoogle Scholar
  • 40 Badreddine RJ, Prasad GA, Wang KK. et al. Prevalence and predictors of recurrent neoplasia after ablation of Barrett’s esophagus. Gastrointest Endosc 2010; 71: 697-703
    CrossrefPubMedGoogle Scholar
  • 41 Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett’s high grade dysplasia and early adenocarcinoma. Am J Gastroenterol 2002; 97: 2998-3006
    CrossrefPubMedGoogle Scholar
  • 42 Dulai PS, Pohl H, Levenick JM. et al. Radiofrequency ablation for long- and ultralong-segment Barrett’s esophagus: A comparative long-term follow-up study. Gastrointest Endosc 2013; 77: 534-541
    CrossrefPubMedGoogle Scholar
  • 43 Bradburn MJ, Deeks JJ, Berlin JA. et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77
    CrossrefPubMedGoogle Scholar
  • 44 Efthimiou O, Rücker G, Schwarzer G. et al. Network meta-analysis of rare events using the Mantel-Haenszel method. Stat Med 2019; 38: 2992-3012
    CrossrefPubMedGoogle Scholar
  • 45 Krishnamoorthi R, Singh S, Ragunathan K. et al. Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy: a systematic review and meta-analysis. Gastrointest Endosc 2016; 83: 1090-1106.e3
    CrossrefPubMedGoogle Scholar
  • 46 Cotton CC, Wolf WA, Pasricha S. et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: endoscopic findings and anatomic location. Gastrointest Endosc 2015; 81: 1362-1369
    CrossrefPubMedGoogle Scholar
  • 47 Corley DA, Mehtani K, Quesenberry C. et al. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013; 145: 312-319.e1
    CrossrefPubMedGoogle Scholar
  • 48 Alshelleh M, Inamdar S, McKinley M. et al. Incremental yield of dysplasia detection in Barrett’s esophagus using volumetric laser endomicroscopy with and without laser marking compared with a standardized random biopsy protocol. Gastrointest Endosc 2018; 88: 35-42
    CrossrefPubMedGoogle Scholar
  • 49 ASGE Practice Committee. Qumseya B, Sultan S. et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc 2019; 90: 335-359.e2
    CrossrefPubMedGoogle Scholar
  • 50 Winans CS. Manometric asymmetry of the lower-esophageal high-pressure zone. Am J Dig Dis 1977; 22: 348-354
    CrossrefPubMedGoogle Scholar
  • 51 Schneider JH, Grund KE, Becker HD. Lower esophageal sphincter measurement in four different quadrants in normals and patients with achalasia. Dis Esophagus 1998; 11: 120-124
    CrossrefPubMedGoogle Scholar
  • 52 Katsube T, Adachi K, Furuta K. et al. Difference in localization of esophageal mucosal breaks among grades of esophagitis. J Gastroenterol Hepatol 2006; 21: 1656-1659
    CrossrefPubMedGoogle Scholar
  • 53 Shaheen NJ, Falk GW, Iyer PG. et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111: 30-50 ; quiz 51
    CrossrefPubMedGoogle Scholar